Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04144907 | Protein Needs Study | recruiting | N/A | 40 | University of AlbertaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | recruiting | Phase 2 | 454 | AstraZenecaINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT06102902 |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer |
| recruiting |
| Phase 1 |
| 30 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06337552 | High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) | active not recruiting | N/A | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06534918 | Precise Oncology Interventions in Nutrition and Training (OnPoint)(OnPoint) | recruiting | N/A | 306 | University of MiamiOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06843655 | Radiological Markers in Locally Advanced Rectal Cancer(LARC) | active not recruiting | — | 179 | IRCCS San RaffaeleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04815525 | The Longterm Risk of Advanced Colorectal Neoplasia After Colonoscopy - A Population-based Cohort Study in Hong Kong(ACNC) | recruiting | — | 5,000 | Chinese University of Hong KongOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05653960 | Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry | not yet recruiting | — | 2,500 | Chinese University of Hong KongOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,130 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07227636 | A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy | recruiting | Phase 2 | 284 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07255066 | Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial(OPT-EPA) | recruiting | N/A | 118 | University of EdinburghOTHER | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07623174 | A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland | recruiting | — | 110 | TakedaINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07653685 | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. | recruiting | Phase 1 / Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07728019 | Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM | recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy(NEXERA-204) | not yet recruiting | Phase 2 | 40 | Incyte CorporationINDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833319 | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer(PKUCH-R10) | recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07834268 | Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS) | active not recruiting | N/A | 1,250 | Fifth Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07834385 | Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis(NTLC75-ITA) | not yet recruiting | — | 40 | University Hospital of SplitOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT06349590 | Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery(DIET) | recruiting | Phase 1 / Phase 2 | 80 | University of ChicagoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07132463 | Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study | recruiting | Phase 3 | 196 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07200141 | Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer(SIB-NCRT) | recruiting | Phase 2 | 156 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 100 | SOTIO Biotech a.s.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease(STELLAR-316) | recruiting | Phase 3 | 600 | ExelixisINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830407 | Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer | recruiting | — | 100 | Pierian BiosciencesINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02874885 | Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer | active not recruiting | — | 341 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06271941 | Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps(ABLATION) | recruiting | N/A | 892 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | recruiting | Early Phase 1 | 30 | University of ArizonaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07676383 | Precision Navigation to Improve Community Cancer Screening Participation | recruiting | N/A | 1,500 | Hunan Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829081 | Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors(RESIST) | recruiting | — | 234 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06462183 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | active not recruiting | Phase 1 | 105 | Rgenta Therapeutics IncINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06529523 | Tislelizumab in People With Colorectal Cancer | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07153016 | LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer | active not recruiting | N/A | 20 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | recruiting | Phase 1 | 574 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07622771 | Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial | recruiting | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07780305 | ABCSG R07 Rectal Cancer Registry(ABCSG R07 RCR) | not yet recruiting | — | 600 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825766 | The Role of Total Abdominal Autonomic Nerve Preservation During the Resection of Right/Left Colon Cancer: Prospective Clinical Trial | active not recruiting | — | 200 | Fudan UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826611 | The Diagnostic Accuracy of the Device Under Development MULTISCOPE(MULTISCOPE) | not yet recruiting | N/A | 30 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT03955510 | Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis(AFT) | active not recruiting | N/A | 12 | Rush University Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05081024 | Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer | recruiting | — | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05343013 | TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials